Drug
Sar245408
Sar245408: highest development phase Phase 1, developed by Sanofi. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Sanofi
Trials
| Drug | Phase | Indication |
|---|---|---|
| SAR245408 (XL147) NCT01357330 | Phase 1 | Solid Tumors |
Latest
No recent events.
Follow Sar245408 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.